Sun Acquisitions

AUGUST 22, 2024

To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A).

M&A 52

M&A Management Mergers and Acquisitions Food 52

Devensoft

AUGUST 22, 2023

Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. Few would disagree the American healthcare sector faces a great many challenges in terms of accessibility, affordability, and quality of care.

Healthcare 52

Healthcare M&A Valuation Medical 52

Software Equity Group

JANUARY 22, 2024

In this post, we’ll offer further insights into what’s driving the need for healthcare SaaS solutions and how business owners can capitalize on heightened activity in healthcare M&A. Few would disagree the American healthcare sector faces a great many challenges in terms of accessibility, affordability, and quality of care.

Healthcare 52

Healthcare M&A Valuation Medical 52

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 22, 2020

2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2

M&A 40

M&A Pharmaceutical Acquisitions Capital 40